156294-36-9

Name	Larotaxel
Synonyms	XRP9881 Larotaxel PNU 100940 Benzenepropanoic acid, β-[[(1,1-dimethylethoxy)carbonyl]amino]-α-hydroxy-, (1S,2S,4S,7R,8aR,9aS,10aR,12aS,12bR)-7,12a-bis(acetyloxy)-1-(benzoyloxy)-1,3,4,7,8,9,9a,10,10a,12,12a,12b-dodecahydro-2-hydroxy-5,13,13-trimethyl-8-oxo-2,6-methano-2H-cyclodeca[3,4]cyclopropa[4,5]benz[1,2-b]oxet-4-yl ester
CAS	156294-36-9

Molecular Formula	C45H53NO14
Molar Mass	831.9
Density	1.37
Melting Point	170 - 174°C (dec.)
Boling Point	889.3±65.0 °C(Predicted)
Solubility	Soluble in DMSO, insoluble in water
Appearance	Form Solid, color White to Off-White
pKa	11.20±0.46(Predicted)
Storage Condition	-20°C Freezer
MDL	MFCD00925691
Physical and Chemical Properties	Bioactive Larotaxel (XRP9881) is a taxane analog with pre-clinical activity against taxane-resistant breast cancer. Larotaxel (XRP9881) exerts its cytotoxic effect by promoting tubulin assembly and stabilizing microtubules, and finally leads to cell death through apoptosis. Larotaxel (XRP9881) has the ability to cross the blood-brain barrier and has much lower affinity for P-glycoprotein 1 than Docetaxel.
Use	Introduction Lailontaisin is a kind of purple alkyl analog with more novel skeleton structure. The results of biological research show that its in vitro anti-cancer activity is significantly better than that of paclitaxel and docetaxel, and the results of its in vivo activity research are also exciting. In the second phase of clinical research, people are very satisfied with the significant anti-cancer effect and low side effects of leontazine, especially for ovarian cancer and breast cancer that overexpress multidrug resistance genes.